Triple Negative Breast NeoplasmsPSY-ONC TNBCNCT04669522
Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer
An observational study of Triple Negative Breast Neoplasms, run by Pius-Hospital Oldenburg.
Trial summary
It has been established that chronic stress can take a toll on one's health. Furthermore, when an someone falls ill, it is believed that the way that they handle stress and/or adversity can positively or negatively impact the course of their disease. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Triple Negative Breast Neoplasms
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Dec 2020to Dec 2021
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The retrospective cohort will be composed of a minimum of 50 patients diagnosed with TNBC and treated in the University Hospital for Gynecology, Pius-Hospital Oldenburg, between 01.01.2015-31.12.2019.
Who may be able to join
- a confirmed diagnosis of TNBC, with the ability to speak and understand German, who can give informed consent, and who were treated in the University Hospital for Gynecology, Pius-Hospital Oldenburg, between 01.01.2015-31.12.2019
Who cannot join
- 1) any woman with an unconfirmed TNBC diagnosis, 2) woman whose medical records are lacking clinical and/or pathological variables of interest, 3) patients with current or previous mood disorder, psychosis, anxiety disorder, psychosis, anxiety disorder, or substance abuse disorder according to the DSM V, Diagnostic and Statistical Manual of Mental Disorders, and 5) all women who currently make use of psychotropic agents or psychiatric drugs.
About this study
Official title: How do Psychological Factors Interact With the Oncological Outcomes of Women With Triple-negative Breast Cancer?
It has been established that chronic stress can take a toll on one's health. Furthermore, when an someone falls ill, it is believed that the way that they handle stress and/or adversity can positively or negatively impact the course of their disease. Against the background of these findings, this study aims to explore how (1) cumulative lifetime stress exposure, (2) coping response, (3) perceived social support, and (4) and overall psychological well-being may relate to the oncological outcomes of women diagnosed with triple negative breast cancer (TNBC).
Patients treated for TNBC between 01.01.2015-31.12.2019 at the University Clinic for Gynecology at Pius-Hospital Oldenburg will be asked to complete four questionnaires corresponding to the abovementioned psychological aspects. The results of these questionnaires will be analyzed together with the clinical patient data and tumor characteristics (such as type, size, etc.) to explore whether there is a tendency between one or more of the above-mentioned psychosocial aspects and the course of the disease (e.g. a disease recurrence within one year after the initial diagnosis (yes / no), the duration of the disease-free or progression-free period).
Read more
As there is an existing body of evidence supporting a relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have faced more stressful/adverse life events, 2) those who present inadequate/inappropriate coping skills, 3) report less social support, and 4) poorer overall psychological well-being.
If a potential connection between psychosocial factors and the course of the TNBC is identified, further disease specific, it will aid in the development of disease-specific, health-promoting measures to better support this particular patient group. This is of great importance, as TNBC is generally associated with clinically aggressive behavior and a worse prognosis compared to other breast cancer subtypes.
Read the detailed description
Triple negative breast cancer (TNBC) is a highly heterogeneous subtype, which exhibits aggressive clinical behavior and generally carries a poor prognosis. As it lacks hormone receptors expression (estrogen and progesterone receptors) and amplification of the Human epidermal growth factor receptor 2 (HER2), targeted therapies are lacking. Thus, the identification of any modifiable factors which may influence the course of the disease is critical both in improving the quality of care and the patient's quality of life. In addition to lifestyle factors, such as diet and exercise habits, psychological factors, such as cumulative lifetime stress, coping response, perceived social support, and overall psychological well-being may also influence cancer progression.
While it is known that stress can directly upregulate certain immune mechanisms, it is suspected that a patient's coping response, perceived social support, and general psychological well-being may have an indirect influence on cancer progression via altered health-related behaviors. For example, during stressful periods, alcohol consumption may rise, sleep quality may be diminished, nutritional needs may not be properly met, and exercise may be avoided. As a group, TNBC patients face additional challenges not experienced by other BC patients. Due to the disease's poor prognosis, its relatively new status as a BC subtype (first mention in 2005), and the lack of targeted treatments; patients may experience an increased stress-response following their diagnosis. For instance, it is known that an event induces a stress response when it involves novelty and unpredictability, a lack of sense of control, and threats to the sense of self; elements that are clearly emphasized in TNBC.
To promote the development of psycho oncological strategies tailored towards women in this particular patient group, this study aims to explore any trends which might be indicative of an interaction between psychological aspects and the oncological outcomes of patients treated for TNBC between 01.01.2015-31.12.2019, at Pius Hospital, in Oldenburg, Germany. Because we intend to evaluate a retrospective cohort of patients, the psychological instruments were chosen and slightly adapted to target past events (stress across life span and social support) and stable traits (psychological well-being, coping).
As there is an existing body of evidence supporting the relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have had more adverse life events, and 2) those who present inadequate/inappropriate coping skills. Additionally, we intend to explore if other psychological variables mentioned in the literature, including perceived social support and psychological well-being, are also related to the oncological outcomes in our cohort of patients.
This study combines prospective and retrospective approaches since the psychosociological data is to be collected prospectively from a single retrospective cohort of patients. Patients could not be randomized into groups, due to the retrospective nature of the study. Considering that all data derived from this study will be numerical, this will be a quantitative analysis. This research is comparative since the patients' clinical outcomes will be analyzed in terms of psychological measures. Lastly, the present study is exploratory as it aims to shed light on the interplay between psychological and clinical aspects in TNBC, as psycho-oncological studies are lacking for this BC subtype.
A list of patient names will be obtained from the hospital's Tumor Documentation Office. Next, patient electronic medical records will be accessed through Pius-Hospital's Orbis Database program according to the name and date of birth of each patient. Demographic and clinical variables of interest will be collected from the clinical charts and recorded on the patient case report form (CRF).
The psychological aspects of interest will be assessed through self-reported questionnaires. (1 computer-based and 3 paper-based questionnaires). Patients will fill out the surveys in a proper setting where privacy will be assured. Questionnaires will not include information which could be directly used to identify participants (i.e. name, DOB), but will instead contain a code which will allow the psychological data to be combined with the respective participant's demographic and clinical variables for the subsequent statistical analysis. After completion, participant's information (pseudonymized) will be transferred to the CRF, and subsequently case data will be transferred to SPSS (software version 26.0) for further statistical analysis.
- Conditions
- Triple Negative Breast Neoplasms
- Keywords
- Psychooncology
- Medical subject headings
- Triple Negative Breast Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Severity Score (OSS)
Cumulative lifetime stress will be quantified as a score (Overall Severity Score; OSS) derived from the Stress and Adversity Inventory (STRAIN) questionnaire (Slavich and Shields, 2018).
Measured: 1 day
Secondary outcomes (1)
Hazard ratio associated with OSS
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2020
- Study startDec 2020 (estimated)
- Primary completionDec 2021 (estimated)
- Study completionDec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Triple Negative Breast NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 50 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Pius-Hospital Oldenburg
- Sponsor type
- University, hospital or other
- Collaborators
- University of Oldenburg
- Responsible party
- Principal investigator, Prof. Dr. Dr. med. Rudy Leon De Wilde, Pius-Hospital Oldenburg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04669522
- Sponsor's protocol ID
- PHDW-006
- Acronym
- PSY-ONC TNBC
- Status last verified
- Dec 2020
- First submitted
- 9 Dec 2020
- Last updated
- 17 Dec 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- How do Psychological Factors Interact With the Oncological Outcomes of Women With Triple-negative Breast Cancer?
- ClinicalTrials.gov ID
- NCT04669522
- Acronym / sponsor ID
- PSY-ONC TNBC / PHDW-006
- Conditions
- Triple Negative Breast Neoplasms
- Keywords
- Psychooncology
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Pius-Hospital OldenburgUniversity, hospital or other
- Collaborators
- University of Oldenburg
- Study start
- Dec 2020 (estimated)
- Primary completion
- Dec 2021 (estimated)
- Study completion
- Dec 2021 (estimated)
- First posted
- 17 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It has been established that chronic stress can take a toll on one's health. Furthermore, when an someone falls ill, it is believed that the way that they handle stress and/or adversity can positively or negatively impact the course of their disease. Against the background of these findings, this study aims to explore how (1) cumulative lifetime stress exposure, (2) coping response, (3) perceived social support, and (4) and overall psychological well-being may relate to the oncological outcomes of women diagnosed with triple negative breast cancer (TNBC).
Patients treated for TNBC between 01.01.2015-31.12.2019 at the University Clinic for Gynecology at Pius-Hospital Oldenburg will be asked to complete four questionnaires corresponding to the abovementioned psychological aspects. The results of these questionnaires will be analyzed together with the clinical patient data and tumor characteristics (such as type, size, etc.) to explore whether there is a tendency between one or more of the above-mentioned psychosocial aspects and the course of the disease (e.g. a disease recurrence within one year after the initial diagnosis (yes / no), the duration of the disease-free or progression-free period).
As there is an existing body of evidence supporting a relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have faced more stressful/adverse life events, 2) those who present inadequate/inappropriate coping skills, 3) report less social support, and 4) poorer overall psychological well-being.
If a potential connection between psychosocial factors and the course of the TNBC is identified, further disease specific, it will aid in the development of disease-specific, health-promoting measures to better support this particular patient group. This is of great importance, as TNBC is generally associated with clinically aggressive behavior and a worse prognosis compared to other breast cancer subtypes.
Detailed description
Triple negative breast cancer (TNBC) is a highly heterogeneous subtype, which exhibits aggressive clinical behavior and generally carries a poor prognosis. As it lacks hormone receptors expression (estrogen and progesterone receptors) and amplification of the Human epidermal growth factor receptor 2 (HER2), targeted therapies are lacking. Thus, the identification of any modifiable factors which may influence the course of the disease is critical both in improving the quality of care and the patient's quality of life. In addition to lifestyle factors, such as diet and exercise habits, psychological factors, such as cumulative lifetime stress, coping response, perceived social support, and overall psychological well-being may also influence cancer progression.
While it is known that stress can directly upregulate certain immune mechanisms, it is suspected that a patient's coping response, perceived social support, and general psychological well-being may have an indirect influence on cancer progression via altered health-related behaviors. For example, during stressful periods, alcohol consumption may rise, sleep quality may be diminished, nutritional needs may not be properly met, and exercise may be avoided. As a group, TNBC patients face additional challenges not experienced by other BC patients. Due to the disease's poor prognosis, its relatively new status as a BC subtype (first mention in 2005), and the lack of targeted treatments; patients may experience an increased stress-response following their diagnosis. For instance, it is known that an event induces a stress response when it involves novelty and unpredictability, a lack of sense of control, and threats to the sense of self; elements that are clearly emphasized in TNBC.
To promote the development of psycho oncological strategies tailored towards women in this particular patient group, this study aims to explore any trends which might be indicative of an interaction between psychological aspects and the oncological outcomes of patients treated for TNBC between 01.01.2015-31.12.2019, at Pius Hospital, in Oldenburg, Germany. Because we intend to evaluate a retrospective cohort of patients, the psychological instruments were chosen and slightly adapted to target past events (stress across life span and social support) and stable traits (psychological well-being, coping).
As there is an existing body of evidence supporting the relationship between stress and the immune system, we expect to see the poorest oncological outcomes in patients who 1) have had more adverse life events, and 2) those who present inadequate/inappropriate coping skills. Additionally, we intend to explore if other psychological variables mentioned in the literature, including perceived social support and psychological well-being, are also related to the oncological outcomes in our cohort of patients.
This study combines prospective and retrospective approaches since the psychosociological data is to be collected prospectively from a single retrospective cohort of patients. Patients could not be randomized into groups, due to the retrospective nature of the study. Considering that all data derived from this study will be numerical, this will be a quantitative analysis. This research is comparative since the patients' clinical outcomes will be analyzed in terms of psychological measures. Lastly, the present study is exploratory as it aims to shed light on the interplay between psychological and clinical aspects in TNBC, as psycho-oncological studies are lacking for this BC subtype.
A list of patient names will be obtained from the hospital's Tumor Documentation Office. Next, patient electronic medical records will be accessed through Pius-Hospital's Orbis Database program according to the name and date of birth of each patient. Demographic and clinical variables of interest will be collected from the clinical charts and recorded on the patient case report form (CRF).
The psychological aspects of interest will be assessed through self-reported questionnaires. (1 computer-based and 3 paper-based questionnaires). Patients will fill out the surveys in a proper setting where privacy will be assured. Questionnaires will not include information which could be directly used to identify participants (i.e. name, DOB), but will instead contain a code which will allow the psychological data to be combined with the respective participant's demographic and clinical variables for the subsequent statistical analysis. After completion, participant's information (pseudonymized) will be transferred to the CRF, and subsequently case data will be transferred to SPSS (software version 26.0) for further statistical analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The retrospective cohort will be composed of a minimum of 50 patients diagnosed with TNBC and treated in the University Hospital for Gynecology, Pius-Hospital Oldenburg, between 01.01.2015-31.12.2019.
Key inclusion criteria (1 listed)
- a confirmed diagnosis of TNBC, with the ability to speak and understand German, who can give informed consent, and who were treated in the University Hospital for Gynecology, Pius-Hospital Oldenburg, between 01.01.2015-31.12.2019
Key exclusion criteria (1 listed)
- 1) any woman with an unconfirmed TNBC diagnosis, 2) woman whose medical records are lacking clinical and/or pathological variables of interest, 3) patients with current or previous mood disorder, psychosis, anxiety disorder, psychosis, anxiety disorder, or substance abuse disorder according to the DSM V, Diagnostic and Statistical Manual of Mental Disorders, and 5) all women who currently make use of psychotropic agents or psychiatric drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Severity Score (OSS)
Time frame: 1 day
Cumulative lifetime stress will be quantified as a score (Overall Severity Score; OSS) derived from the Stress and Adversity Inventory (STRAIN) questionnaire (Slavich and Shields, 2018).
1 secondary outcome
Hazard ratio associated with OSS
Time frame: 1 day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2020.
Related trials for Triple Negative Breast Neoplasms
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Triple Negative Breast Neoplasms, run by Pius-Hospital Oldenburg.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Severity Score (OSS) (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2020.